Register | Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Precision Medicine
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | Upfront Therapy for mRCC

Specialties >>

AML
Biomarker-Driven Lung Cancer
Bladder Cancer
Breast Cancer
CAR T-Cell Therapy
CLL
Colorectal Cancer
DLBCL
EGFR+ Lung Cancer
Follicular Lymphoma
Genomic Testing
GI Cancers
Gynecologic Cancers
HCC
Hematology
Immunotherapy
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
MPNs
Multiple Myeloma
Prostate Cancer
Renal Cell Carcinoma
Skin Cancers
Thyroid Cancers
More >>

Partners >>

Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up

Targeted Therapies in Oncology
June 2019

Clinical Articles

Erdafitinib Approval in Urothelial Carcinoma Opens Door to Future Targeted Therapies
Tumor Characteristics May Help Guide Therapy Choice in HCC
Burris Calls for Greater Adoption of NGS by Community Oncologists
Costs at Hospital-Based Oncology Practices Continue to Outpace Those of Community Cancer Clinics
Novel Combinations Explored in CRC With Rare Gene Mutations
Expert Explores Role of Radionuclide Therapy in Well-Differentiated Neuroendocrine Tumors
Strategies to Engage Underrepresented Populations Improves Inclusivity in Clinical Trials
Treatment Patterns at End of Life Explored in Large, National Database
Monitoring of ctDNA in Patients With Bladder Cancer Has Potential to Assist Therapy Selection
FDA Issues Draft Guidance to Broaden Clinical Trial Inclusion
Sophisticated Risk Assessment and Prophylactic Strategies Needed for CNS Relapse in DLBCL
Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.